Trial · NCT04524689
Results by group64
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 64
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab | 0 | Participants | ||
| All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab | 0 | Participants | ||
| All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin | 0 | Participants | ||
| All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin | 0 | Participants | ||
| All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | 0 | Participants | ||
| All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | 1 | Participants | ||
| Doublet Cohort: Objective Response Rate (ORR) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab | 47.8 | 95% Confidence Interval 26.82 to 69.41 | percentage of participants | |
| Doublet Cohort: Objective Response Rate (ORR) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab | 0 | 95% Confidence Interval 0.00 to 84.19 | percentage of participants | |
| Quadruplet Cohort: Objective Response Rate | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | 59.1 | 95% Confidence Interval 36.35 to 79.29 | percentage of participants | |
| Quadruplet Cohort: Objective Response Rate | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | 66.7 | 95% Confidence Interval 9.43 to 99.16 | percentage of participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab | Any TEAE | 23 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab | Any TEAE | 2 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin | Any TEAE | 6 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin | Any TEAE | 1 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | Any TEAE | 22 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed | Any TEAE | 3 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab | Any TESAE | 9 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab | Any TESAE | 0 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin | Any TESAE | 1 | Participants | |
| All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin | Any TESAE | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04524689/results